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Abstract
Background: In any animal model of human disease a positive control therapy that demonstrates efficacy in both the
animal model and the human disease can validate the application of that animal model to the discovery of new
therapeutics. Such a therapy has recently been reported by Fornai et al. using chronic lithium carbonate treatment and
showing therapeutic efficacy in both the high-copy SOD1G93A mouse model of familial amyotrophic lateral sclerosis (ALS),
and in human ALS patients.
Methodology/Principal Findings: Seeking to verify this positive control therapy, we tested chronic lithium dosing in a
sibling-matched, gender balanced, investigator-blinded trial using the high-copy (average 23 copies) SOD1G93A mouse
(n=27–28/group). Lithium-treated mice received single daily 36.9 mg/kg i.p. injections from 50 days of age through death.
This dose delivered 1 mEq/kg (6.94 mg/kg/day lithium ions). Neurological disease severity score and body weight were
determined daily during the dosing period. Age at onset of definitive disease and survival duration were recorded. Summary
measures from individual body weight changes and neurological score progression, age at disease onset, and age at death
were compared using Kaplan-Meier and Cox proportional hazards analysis. Our study did not show lithium efficacy by any
measure.
Conclusions/Significance: Rigorous survival study design that includes sibling matching, gender balancing, investigator
blinding, and transgene copy number verification for each experimental subject minimized the likelihood of attaining a false
positive therapeutic effect in this standard animal model of familial ALS. Results from this study do not support taking
lithium carbonate into human clinical trials for ALS.
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Introduction
Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease, ALS
[OMIM 105400]) is a degenerative neuromuscular disorder for
which there is currently no satisfactory treatment. A proportion of
familial cases of ALS have been linked to mutations in the
cytoplasmic superoxide dismutase SOD1 (OMIM 147450). Animal
models of the familial disease have been used to explore
mechanisms of disease onset and progression and to identify
potential therapeutics. In any animal model of human disease, a
positivecontroltherapythathasbeendemonstrated toshowefficacy
in both the animal model and the human disease, provides a
valuable tool that can be used to validate the application of that
animal model to the discovery of new therapeutics. Such a therapy
hasrecentlybeenreported byFornai,et al. [1]using chroniclithium
carbonate treatment and showing therapeutic efficacy in both the
high-copy SOD1G93A mouse model of familial ALS and in human
patients. Other investigators [2,3] have also shown therapeutic
efficacy using chronic lithium treatment in this mouse model.
In addition, there is a reasonable basis in the scientific literature for
relevant targets and effects of lithium that suggests it could be
therapeutic in neurodegenerative diseases [4–8]. Compelled by the
potential for having a positive control therapy against which to
measure other potential therapeutics, and from which to derive
genomic targets using gene profiling methods, we conducted the
current study. Although lithium’s low therapeutic index had the
potential to elicit untoward effects during a 4-month survival study,
we sought to duplicate exactly the dosing regimen used by Fornai et
al. [1] because it showed unequivocal efficacy, and this efficacy was
linked toefficacyinALSpatients.We tested chroniclithiumdosing in
a sibling-matched, gender balanced, investigator-blinded trial using
the high-copy SOD1G93A mouse, a standard animal model of
familial ALS [9]. Our study did not show efficacy by any measure.
Results
Chronic intraperitoneal administration of lithium carbonate
started at 50 days of age and continued until death. All 28/28 drug
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completed the study. One vehicle control animal was sacrificed
early at the request of the staff Veterinarian and removed from the
study as a non-ALS death.
Body Weight
Failure to maintain body weight is an indicator of disease onset and
p r o g r e s s i o ni nt h eS O D 1
G93A mouse model of ALS. The average
starting body weight (age 50 days) was 19.560.57 and 19.860.53 g for
the vehicle control- and lithium carbonate-treated groups, respectively
(females 16.960.34 and 17.360.30; males 22.060.43 and 22.360.38).
Treatment group daily average change in body weight over
time is plotted through the age at which the last animal died in
Figure 1 (top panels). To prevent decomposition of the mean
values as animals began to die, last values were carried forward
during computation of the means. Drug group animals showed
slightly lesser body weight gain (up to 0.5 g) during the ascent to
peak body weight. This effect was greater in males than in females.
When examined separately for each animal, peak body weight
occurred at different ages. When body weight change over time was
fitted for each animal and measures derived from the individual
curves, time to peak body weight and time from peak to terminal
body weight were similar in both groups (Table 1). The average
maximum increase from initial body weight (CTRL 3.560.2,
DRUG 3.360.2 g, p=0.5000) and age at peak body weight
(CTRL 95.162.0, DRUG 95.261.8 days of age, p=0.9911) were
similar in both groups. Median weight change from peak body
weight to terminal body weight (CTRL 2.360.2, DRUG 2.260.2,
p=0.7520) was also similar in both groups (Student’s 2-tailed
independent t-test). Based on individual changes in body weight,
chronic dosingwith lithiumcarbonatehad noeffecton disease onset
or progression in these studies. However, group average body
weights suggested that mice inthelithium-treated group maintained
body weight less effectively by as much as 0.5 g.
Neurological Severity Score
The ALS-TDI neurological scoring system was designed to provide
an unbiased assessment of disease onset, progression and severity of
paralysis. Treatment group daily average neurological disease severity
score over time is plotted through the age at which the last animal died
in Figure 1 (bottom panels). To prevent decomposition of the mean
values as animals began to die, last values were carried forward during
computation of the means. Drug group animals showed a slightly
more rapid progression in neurological disease severity score during
the early onset phase of the disease. This effect was prolonged into the
later stages of disease in females.
Days spent at each neurological severity score level were
determined for individual mice. These were compared for the
vehicle control- and lithium carbonate-treated groups in Figure 2.
Drug group animals spent fewer days at the asymptomatic Score0
level and more days at the early symptomatic Score1 level than
vehicle control group mice. This effect was greater in males than in
Figure 1. Daily average body weight change and neurological severity score in SOD1
G93A mice. Group average change from initial body
weight (top panels) and neurological disease severity score (bottom panels) are compared over time from age at study start to age at last death. Left
panels show data from all animals (All); middle and right panels show data from females (F) and males (M), respectively. Vehicle control (CTRL)
animals received daily 0.2 mL i.p. injections of isotonic saline. Lithium-treated (DRUG) animals received daily 36.9 mg/kg i.p. injections of lithium
carbonate dissolved in isotonic saline. Because animals died at different ages, group means were computed after carrying forward last values for each
animal until the last animal died. Results of statistical analysis for summary measures taken from these data are given in Table 1.
doi:10.1371/journal.pone.0006489.g001
Chronic Lithium in ALS Mice
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by categorical analysis (Table 2).
Disease Onset and Survival
The proportion of mice that progressed to definitive onset of
symptomatic neurological disease over time is shown in Figure 3.
Overall, there was no statistically significant difference in onset of
disease. Drug group females tended to show earlier (median 7
days) onset. However, this difference was not statistically
significant (Table 3).
The proportion of mice surviving over time is shown in Figure 4.
There was no statistically significant difference in survival
proportions over time when comparing vehicle control- with
lithium carbonate-treated high-copy SOD1G93A mice (Table 3).
Table 1. Time-to-Event Analysis for Peak Change in Body Weight.
1, 2
Parameter Subjects Trtmnt N Median Time Risk Ratio Test Prob.ChiSq
Time to Peak (days) All CTRL 27 42 1.04 Log-Rank 0.8203
DRUG 28 46 0.96 Wilcoxon 0.7747
Likelihood 0.8900
Female CTRL 13 52 0.67 Log-Rank 0.3200
DRUG 14 47 1.49 Wilcoxon 0.6798
Likelihood 0.3340
Male CTRL 14 38 1.23 Log-Rank 0.5781
DRUG 14 42 0.81 Wilcoxon 0.7482
Likelihood 0.5926
Peak to Death (days) All CTRL 27 29 0.99 Log-Rank 0.9683
DRUG 28 31 1.01 Wilcoxon 0.4999
Likelihood 0.9710
Female CTRL 13 28 0.99 Log-Rank 0.9733
DRUG 14 29 1.01 Wilcoxon 0.7713
Likelihood 0.9750
Male CTRL 14 29 1.22 Log-Rank 0.9490
DRUG 14 34 0.82 Wilcoxon 0.3935
Likelihood 0.6975
1Testing Terms: In Kaplan-Meier analysis the Log-Rank test places more weight on later event times; the Wilcoxon test places more weight on early event times and is
the optimum rank test if the error distribution is logistic. Prob.ChiSq lists the probability of obtaining, by chance alone, a Chi-square value greater than the one
computed if the time-to-event functions are the same for all groups. In Cox proportional hazards analysis a Risk Ratio of 1.00 occurs when timing is likely identical in
the two groups. The Effect Likelihood Test is the likelihood-ratio Chi-square test on the null hypothesis that the parameter estimate for the Treatment covariate is zero
(no effect of treatment). Testing term descriptions are taken from the JMPH 7.0.1 Help file.
2Peak change from initial body weight was detected after spline smoothing (stiffness 100) of each animal’s body weight change over time during the period from study
start to death.
doi:10.1371/journal.pone.0006489.t001
Figure 2. Average number of days spent at each neurological severity score level in SOD1
G93A mice. Left panel shows data from all
animals (All); middle and right panels show data from females (F) and males (M), respectively. Vehicle control (CTRL) animals received daily 0.2 mL i.p.
injections of isotonic saline. Lithium-treated (DRUG) animals received daily 36.9 mg/kg i.p. injections of lithium carbonate dissolved in isotonic saline.
Data are treatment group means6s.e.m.. Scores advance in severity from 0 to 4. Results of statistical analysis for these data are given in Table 2.
doi:10.1371/journal.pone.0006489.g002
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Supporting data are available in Dataset S1. This is a 976 KB
Microsoft Excel notebook file named ‘‘Lithium Dataset S1.xls’’.
Databases containing all raw and derived data and tables
summarizing the data in detail are provided in separate tabs of
the Excel notebook. Tabs in the file contain the following
elements: DB1 (indexed database), DB2 (list database), BW
(mean body weight over time), BWCh (mean body weight
change over time), SmBWch (spline 100 smoothed body weight
change over time), NSAve (mean neurological severity score
over time), BWPeak (peak body weight changes), BWPeakAve
( m e a np e a kb o d yw e i g h tc h a n g e s ) ,N e u r o A l l( d a y sa n dm e d i a n
age at score by mouse), NeuroAve (mean days and median age at
score).
Discussion
Any animal model of disease capable of predicting therapeutic
outcomes in the human patient is a valuable tool that can be applied
tothediscoveryofnew therapeutics.Encouraged bytherecent report
from Fornai et al. [1] of a treatment that has been demonstrated to
show efficacy in both the animal model and the human disease, we
sought to duplicate the exact therapeutic regimen used in their mouse
study. Fornai, et al. used chronic lithium carbonate treatment and
Table 2. Neurological Severity Score: Categorical Analysis of Days at Score by Treatment.
1, 2
Subjects Parameter Treatment Score0 Score1 Score2 Score3 Score4
All Frequency CTRL 1161 645 175 84 27
DRUG 1049 804 198 104 28
Share of Responses CTRL 0.56 0.31 0.08 0.04 0.01
DRUG 0.48 0.37 0.09 0.05 0.01
Prob.ChiSq 0.0012 0.0005 0.4008 0.2259 1.0000
Females Frequency CTRL 612 301 100 33 13
DRUG 586 355 104 68 14
Share of Responses CTRL 0.58 0.28 0.09 0.03 0.01
DRUG 0.52 0.32 0.09 0.06 0.01
Prob.ChiSq 0.0420 0.2455 0.8033 0.0016 1.0000
Males Frequency CTRL 549 344 75 51 14
DRUG 463 449 94 36 14
Share of Responses CTRL 0.53 0.33 0.07 0.05 0.01
DRUG 0.44 0.43 0.09 0.03 0.01
Prob.ChiSq 0.0068 0.0002 0.1434 0.1069 1.0000
1Testing Terms: Frequency is the number of occurrences of that score for the entire treatment group over the duration of the study. Share of Responses is the
proportion of total responses by the treatment group that occurred at each Score level. Prob.ChiSq lists the probability of obtaining, by chance alone, a Chi-square
value greater than the one computed if the score frequencies are the same for both Treatment groups at group size minus one degrees of freedom.
2Neurological scores were assigned as described in detail in Materials and Methods. Neurological disease severity increases from 0–4. Score0 is asymptomatic, Score4 is
moribund.
doi:10.1371/journal.pone.0006489.t002
Figure 3. Kaplan-Meier time-to-failure plot for onset of symptomatic neurological disease in SOD1
G93A mice. The age at which mice
attain a neurological severity score of 2 is taken to be definitive onset of symptomatic disease. Left panel shows data from all animals (All); middle and
right panels show data from females (F) and males (M), respectively. Vehicle control (CTRL) animals received daily 0.2 mL i.p. injections of isotonic
saline. Lithium-treated (DRUG) animals received daily 36.9 mg/kg i.p. injections of lithium carbonate dissolved in isotonic saline. Results of statistical
analysis for these data are given in the upper portion of Table 3.
doi:10.1371/journal.pone.0006489.g003
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mouse model of familial ALS and in human patients. In our study we
tested chronic lithium dosing in an effectively powered, sibling
matched, gender balanced, transgene copy number verified,
investigator blinded trial using the high-copy SOD1G93A mouse.
However, our study did not show efficacy by any measure.
Both mouse studies employed the same mouse strain (B6SJL-
TgN(SOD1-G93A)1Gur) and lithium salt, formulation, dose,
route, and frequency. We began lithium treatment at 50 days of
age. Fornai et al. began treatment at 75 days of age. They also
noted that they achieve comparable efficacy even when lithium
treatment is started at the onset of motor symptoms. Thus,
variations in the time of treatment start would not be expected to
affect efficacy results, especially if treatment were given from an
earlier age. However, transgene copy number [10] and gender do
seem to affect disease onset and survival duration. Any difference
Table 3. Time-to-Event Analysis for Onset of Neurological Symptoms and for Survival Duration.
1, 2
Parameter Subjects Trtmnt N Median Time Risk Ratio Test Prob.ChiSq
Onset Age (days) All CTRL 27 117 0.90 Log-Rank 0.6345
DRUG 28 114 1.11 Wilcoxon 0.5785
Likelihood 0.7170
Female CTRL 13 121 0.60 Log-Rank 0.1876
DRUG 14 114 1.66 Wilcoxon 0.1814
Likelihood 0.2140
Male CTRL 14 113 1.13 Log-Rank 0.7586
DRUG 14 115 0.89 Wilcoxon 0.6293
Likelihood 0.7680
Death Age (days) All CTRL 27 127 1.01 Log-Rank 0.9304
DRUG 28 124 0.99 Wilcoxon 0.9397
Likelihood 0.9730
Female CTRL 13 129 0.84 Log-Rank 0.6587
DRUG 14 124 1.19 Wilcoxon 0.7357
Likelihood 0.6650
Male CTRL 14 126 1.11 Log-Rank 0.7726
DRUG 14 124 0.90 Wilcoxon 0.7483
Likelihood 0.7800
1Testing Terms: In Kaplan-Meier analysis the Log-Rank test places more weight on later event times; the Wilcoxon test places more weight on early event times and is
the optimum rank test if the error distribution is logistic. Prob.ChiSq lists the probability of obtaining, by chance alone, a Chi-square value greater than the one
computed if the time-to-event functions are the same for all groups. In Cox proportional hazards analysis a Risk Ratio of 1.00 occurs when timing is likely identical in
the two groups. The Effect Likelihood Test is the likelihood-ratio Chi-square test on the null hypothesis that the parameter estimate for the Treatment covariate is zero
(no effect of treatment). Testing term descriptions are taken from the JMPH 7.0.1 Help file.
2A neurological score of two in both hind limbs is taken to be the definitive onset of neurological symptoms.
doi:10.1371/journal.pone.0006489.t003
Figure 4. Kaplan-Meier survival plot for age at death in SOD1
G93A mice. Left panel shows data from all animals (All); middle and right panels
show data from females (F) and males (M), respectively. Vehicle control (CTRL) animals received daily 0.2 mL i.p. injections of isotonic saline. Lithium-
treated (DRUG) animals received daily 36.9 mg/kg i.p. injections of lithium carbonate dissolved in isotonic saline. Results of statistical analysis for
these data are given in the lower portion of Table 3.
doi:10.1371/journal.pone.0006489.g004
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treatment groups could cause comparative outcome differences
that are falsely attributed to the drug treatment regimen.
Fornai et al. performed extensive motor function testing as part
of their study. We have avoided such testing because we have
noticed that survival appears shortened in studies that perform
extensive rotarod and other motor functions tests. Multiple
sequential rotarod trials given twice weekly, along with grip
strength and stride length tests, involve more frequent handling
and induced movement than would occur in our trials. Extensive
motor function testing can be considered a kind of environmental
enrichment. Such enrichment has been shown by some to shorten
lifespan in ALS mice [11]. For example, our vehicle control
group’s median survival age (127 days of age) was later than the
Fornai et al. vehicle control median survival age (111 days). Their
vehicle control median survival age even preceded our vehicle
control’s median age at disease onset (117 days of age). Thus, their
experimental conditions appear to promote a shorter lifespan than
ours. Median lifespan of the SJL strain high-copy SOD1G93A
mouse is 130 days, as originally characterized by Gurney [12], and
as maintained by the Jackson Laboratories (personal communica-
tion). The ALS-TDI SOD1G93A SJL colony maintained by
Genzyme Therapeutics has a median lifespan, calculated over
5000 mice, of 131 days. The early disease onset described in
Fornai et al. might be attributable to differences in experimental
conditions described above, to copy-number drift in the colony, to
differences in handling non-ALS deaths, or to the way that the
experimental design dealt with gender or littermate variables.
Our study, that would likely have put steady-state lithium levels
at about 1.5 mM in TBW, did not show efficacy by any measure.
Not surprisingly given lithium’s low therapeutic index, there were
small negative effects in some parameters. This raises the question
about whether a dosing regimen that attained lower levels would
have been more effective. In a review of lithium’s potential
therapeutic role in neurodegenerative diseases Chuang and Manji
[13] point out that much lower lithium levels than those likely
attained in our studies may still be effectively neuroprotective and
also avoid toxicity. For example, four weeks of lithium dosing to
attain steady-state plasma levels of <0.35 mM increased bcl-2
levels in frontal cortex and hippocampus in rats, cultured cortical
neurons could be protected from glutamate excitotoxicity by 0.1–
0.6 mM lithium concentrations, and lithium was significantly
protective in the middle cerebral artery occlusion stroke model at
0.5 mEq/kg. Thus, doses of lithium lower than those required to
treat symptoms of mania have demonstrated neurotrophic and
neuroprotective effects.
A recent publication from the laboratory of Caterina Bendotti
[14] reported studies testing lithium carbonate’s efficacy in high-
copy G93A mice from both the C57BL6/J and 129S2/Sv genetic
backgrounds. Because the Fornai group had shown efficacy in only
male animals, the Bendotti studies were performed in only female
animals. The dosing protocol used was identical to the Fornai
studies. Serial motor function tests, terminal motor neuron counts,
and markers of autophagy and mitochondrial function were
included. No therapeutic effects related to disease onset or
survival, or improvements in anatomical or biochemical measures
of neuroprotection were shown in the C57BL6/J background
mice. Mice from the 129S2/Sv background showed earlier disease
onset and shorter survival times. Thus, no therapeutic effects of
lithium were demonstrated in female SOD1G93A mice from two
strain backgrounds in the Bendotti studies.
Two other recent studies that intended to test treatment
combinations, included lithium treatment groups that appeared
to show efficacy against disease in the G93A mouse. The first, by
Shin et al. [2] used a 0.2% lithium carbonate diet supplement
(taken to be about 200 mg/kg/day) beginning at age 56 days and
using treatment group sizes of 13 mice. Their study showed
about a 10-day delay in onset of symptoms and a similar increase
in mean survival. Gender was not clearly identified in the study
and the differences reported could result from not effectively
gender balancing and litter matching the treatment groups. Our
data show that unbalanced and unmatched groups of this size
would have a 35% chance of showing a positive effect of
treatment by chance alone [9]. Reported beneficial effects on
motor neuron counts were not performed using unbiased
stereological methods.
A second study by Feng, et al. [3], treated high-copy SOD1
G93A ALS mice with twice daily i.p. lithium chloride (60 mg/kg
or 1.41 mEq/kg) injections, starting from 30 days after birth and
continuing until death. Presence or absence of the transgene was
verified by PCR. Mice were randomly divided into treatment
groups, and were matched for littermates with 6 animals (3 males
+ 3 females) in each group. Behavioral observers were blinded.
Like Shin et al., the Feng study showed about a 10 day delay in
onset and a similar increase in mean survival. Our data show that
even with properly balanced and matched treatment groups, the
Feng study would have a 30–40% chance of showing an apparent
treatment effect by chance alone, based on the group size, not
excluding non-ALS deaths and not excluding low copy mice [9].
Although these studies did not measure lithium levels during
treatment, we used pharmacokinetic modeling and simulation,
based on reported parameter estimates for lithium in mice [15], to
predict plasma lithium levels for the dosing regimens used. Based
on these simulations average steady-state plasma Li+ levels would
be predicted to be 0.30 mM for our study, 0.97 mM for the Shin
study, and 1.68 mM for the Feng study. A level of 0.35 mM has
been reported to robustly increase Bcl2 in rat brain (13), levels of
0.1 to 0.2 mM are neuroprotective against glutamate toxicity [16],
and 0.4 to 1.25 mM is considered a safe and effective
concentration range for human use in psychiatric disorders. Thus,
our Fornai, et al.,-based dosing regimen would not likely produce
toxic levels of lithium during treatment and was potentially
sufficient to produce benefit. In our study, at steady state animals
would have spent about 13 h in the concentration range
considered to be effective and acceptably safe, each day. The
Shin study would likely have kept blood lithium levels within the
therapeutic concentration range as well. However, blood levels in
the Feng study would likely have spent about 12 hours each day in
excess of the maximal safe concentration. Peak levels would be
predicted to exceed the maximum safe concentration by about 3.5
fold. Even average daily levels would likely be about 35% above
the safe level. Lithium has a narrow therapeutic index. For
example, when given at 80 mg/kg IP, about twice the dose we
gave in our study, lithium carbonate induced renal insufficiency in
Wistar mice [17]. The failure to maintain adequate fluid intake
can lead to dangerous concentrations of lithium in the body, but
this would likely occur later in disease progression and would be
common to all of the studies.
In summary, despite applying the rigorous methods detailed by
Scott et al. [9] to our therapeutic trial, we were unable to show
efficacy of chronic lithium treatment in the SOD1G93A mouse
ALS model. Only low-grade signs of treatment intolerance were
evident in our study. Differences in gender balance, transgene
copy number, or presence or absence of motor function testing
could account for apparent differences between the two studies.
Lithium may also bear testing using a dosing regimen that attains
lesser, safer, but still potentially neurotrophic, plasma and tissue
concentrations.
Chronic Lithium in ALS Mice
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Although small changes in lithium exposure could produce
toxicity that may offset therapeutic benefit, it is likely that rigorous
survival study design that includes sibling matching, gender
balancing, investigator blinding, and transgene copy number
verification for each experimental subject has minimized the
likelihood of attaining a false positive therapeutic effect in this
standard animal model of familial ALS. The current study did not
identify any therapeutic benefit of chronic lithium treatment with
respect to disease onset, progression of neurological symptoms, or
survival duration, in the high-copy SOD1G93A mouse model.
There was, however, evidence for early onset of low-grade
neurological symptoms and signs of less effective body weight
maintenance in females that may have reflected untoward effects
of lithium treatment.
Materials and Methods
We used the rigorous survival study methods described in detail
by Scott, et al. [9] summarized briefly below, for the current study.
Animals
All procedures were carried out in accordance with guidelines of
the ALSTDI Animal Care and Use Committee and in accordance
with the Institute for Laboratory Animal Research (ILAR) Guide
for Care and Use of Laboratory Animals [18]. High-copy
SOD1G93A transgenic mice bred under contract for ALS TDI
by Genzyme Transgenic Corporation (GTC) were used for this
study. This mouse colony was derived from the B6SJL-
TgN(SOD1G93A)1Gur strain, obtained from The Jackson
Laboratory (Bar Harbor, Maine) and originally produced by
Gurney et al. [12]. GTC maintains the colony by crossing
C57BL/6 sires harboring the transgene with wild-type SJL dams.
Copy number is determined by quantitative Southern blot analysis
of sires, selecting animals with approximately 23 copies. Animals
with a lower copy number are known to have a longer lifespan
[10,12]. To verify presence of the transgene in the F1 progeny, tail
biopsies are collected from 14-day-old pups, then genotyped using
PCR. Transgenic mice are shipped to ALS TDI at 35–45 days of
age. Mice are allowed at least one week to acclimate to ALS TDI’s
animal facility (a 12-h light/dark cycle) before being assigned to a
study. Prior to data analysis, transgene copy number of all animals
in the study was checked using PCR analysis of ear-punch
samples.
Experimental Groups
At 50 days of age mice were separated into Drug Treatment
(DRUG) and Vehicle Control (CTRL) groups. Prior to any
treatment, groups were constituted so as to minimize between-
group variability by using the following criteria. Groups were
balanced with respect to gender (14 males, 14 females per group)
and body weight within gender (mean starting weights were
typically within 0.3 g for either gender between groups). In
addition, groups were age-matched and littermate-matched. Each
male and female in the Drug Treatment group had a
corresponding male and female littermate in the Vehicle Control
group. The study was observer-blinded.
Treatments
Lithium carbonate (Sigma-Aldrich, product number 255823-
100G, purity 99+% A.C.S. reagent) was dissolved at a concentra-
tion of 3.69 mg/mL into isotonic sodium chloride solution. This
formulation was given to animals at a volume of 10 mL/kg body
weight. The lithium treatment group received daily intraperitoneal
36.9 mg/kg lithium carbonate injections. This dosage was
calculated to deliver 6.94 mg/kg/day or 1 mEq/kg/day of lithium
ions. Vehicle control group animals received daily 10 mL/kg
intraperitoneal isotonic sodium chloride injections.
Monitoring Disease Progression
Neurological Score. Neurological scores for both hind legs
were assessed daily for each mouse from 50 days of age. The
neurological score employed a scale of 0 to 4 that was developed
by observation at ALSTDI. Criteria used to assign each score level
were:
Score Criteria
0 Full extension of hind legs away from lateral midline when
mouse is suspended by its tail, and mouse can hold this for 2
seconds, suspended 2–3 times.
1 Collapse or partial collapse of leg extension towards lateral
midline (weakness) or trembling of hind legs during tail
suspension.
2 Toes curl under at least twice during walking of 12 inches, or
any part of foot is dragging along cage bottom/table*.
3 Rigid paralysis or minimal joint movement, foot not being
used for forward motion.
4 Mouse cannot right itself within 30 seconds from either side.
*If one hind leg is scored as 2, food pellets are left on bedding. If
both hind legs are scored as 2, Nutra-GelH (Bio-Serve #S4798) is
provided as food in addition to food pellets on bedding and a long
sipper tube is placed on the water bottle.
Body Weight. Body weight is a sensitive indicator of any
malaise that might result from chronic drug treatment and of
motor impairment that occurs during disease progression. Daily
body weight measurements were recorded for each animal
beginning at 50 days of age.
Survival. Date and cause of death were recorded for each
mouse. For humane reasons, animals are closely monitored and
sacrificed as moribund prior to actual death using criteria for
severe moribundity. To determine duration of survival reliably
and humanely, the moribund state, defined as the inability of mice
to right themselves 30 seconds after being placed on a side (a
neurological score of 4) was used. The moribund mice were scored
as ‘‘dead’’, and were euthanized using carbon dioxide.
Statistical Analysis
To visualize overall changes in body weight and neurological
severity score over time, group mean body weight change and
mean neurological severity score were plotted over time through
the age at which the last death occurred in either treatment group
(Figure 1). Because the animals die at different ages and the timing
of their ascent to peak body weight and descent to minimum body
weight differs markedly from animal to animal, individual body
weight change over time is also shown in Figure S1.
In order to minimize the number of statistical comparisons and
to retain statistical validity in the analysis of correlated serial
measurements on the same subject over time, we determined
relevant summary measures as recommended by Matthews, et al.
[19] and performed statistical analyses on these summary
measures. Summary measures derived from body weight change
over time included time to attain peak body weight and time from
peak body weight to death. These summary measures were
detected from spline-fitted changes in body weight over time for
each individual animal. These time-to-event measures were then
analyzed using Kaplan-Meier survival fit analysis with the Log-
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proportional hazards analysis was also performed to determine
hazard ratios and test for statistical significance of their differences
using the Effect Likelihood Chi Square test.
A summary measure derived from daily ordinal neurological
severity scores counted days at score for each animal at each score
level (Figure 2). These data were analyzed using categorical
analysis where Chi Square tests were used to determine whether
any differences in score frequencies were statistically significant.
Degrees of freedom were based on the number of animals in each
group rather than total number of scores (Table 2).
Time to onset of definitive disease and survival time were also
analyzed using the Kaplan-Meier and Cox proportional hazard
methods (Figures 3, 4, Table 3). Statistical analyses were
performed using JMPH 7.0.1, SAS Institute, Inc., SAS Campus
Drive, Cary, NC 27513, USA. Cox proportional hazard fitting,
using litter as a frailty term, was performed using StataH/IC 10.1,
4905 Lakeway Drive, College Station, TX 77845, USA. P-values
less than 0.05 were taken to be statistically significant.
Supporting data for all measured and derived parameters are
provided in Dataset S1.
Mouse Study Laboratory Information Management
System (LIMS)
All research data related to the animal studies were managed via
LIMS. Any individual mouse, with its unique ID, could be traced
back to its lineage, body weight or neurological score on any given
day, and any other observations noted during its lifetime.
Similarly, tissues from each mouse could also be tracked for
future analysis.
Supporting Information
Figure S1 Smoothed body weight change over time for each
individual animal. Left panels show data from all animals (All);
middle and right panels show data from females (F) and males (M),
respectively. Top three panels show vehicle control animals (red);
bottom three panels show lithium-treated animals (blue).
Found at: doi:10.1371/journal.pone.0006489.s001 (0.72 MB TIF)
Dataset S1 This is a 976 KB Microsoft Excel notebook file
named ‘‘Lithium Dataset S1.xls’’. Databases containing all raw
and derived data and tables summarizing the data in detail are
provided in separate tabs of the Excel notebook. Tabs in the file
contain the following elements: DB1 (indexed database), DB2 (list
database), BW (mean body weight over time), BWCh (mean body
weight change over time), SmBWch (spline 100 smoothed body
weight change over time), NSAve (mean neurological severity
score over time), BWPeak (peak body weight changes), BWPea-
kAve (mean peak body weight changes), NeuroAll (days and
median age at score by mouse), NeuroAve (mean days and median
age at score).
Found at: doi:10.1371/journal.pone.0006489.s002 (1.08 MB
XLS)
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